 Scott Kono
Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 9 | 2022 | 683 | 0.660 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2013 | 1081 | 0.540 |
Why?
| | Head and Neck Neoplasms | 7 | 2014 | 606 | 0.480 |
Why?
| | Lung Neoplasms | 7 | 2022 | 2526 | 0.460 |
Why?
| | Receptors, Fibroblast Growth Factor | 2 | 2011 | 67 | 0.390 |
Why?
| | ErbB Receptors | 5 | 2013 | 614 | 0.310 |
Why?
| | Lymph Node Excision | 1 | 2009 | 171 | 0.280 |
Why?
| | Lymphatic Metastasis | 1 | 2009 | 352 | 0.280 |
Why?
| | Empyema, Pleural | 1 | 2007 | 12 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1692 | 0.230 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 801 | 0.220 |
Why?
| | Quinazolines | 2 | 2013 | 251 | 0.180 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2021 | 23 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2129 | 0.170 |
Why?
| | Pyrazoles | 2 | 2013 | 423 | 0.160 |
Why?
| | Sulfonamides | 2 | 2013 | 513 | 0.160 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2011 | 234 | 0.150 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 261 | 0.150 |
Why?
| | Sirolimus | 2 | 2014 | 276 | 0.120 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1389 | 0.120 |
Why?
| | Multi-Institutional Systems | 1 | 2014 | 9 | 0.110 |
Why?
| | Adenocarcinoma | 2 | 2013 | 940 | 0.110 |
Why?
| | SEER Program | 2 | 2013 | 227 | 0.110 |
Why?
| | Carboplatin | 1 | 2014 | 144 | 0.110 |
Why?
| | Social Class | 1 | 2015 | 282 | 0.100 |
Why?
| | Chemoprevention | 1 | 2013 | 92 | 0.100 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2013 | 28 | 0.100 |
Why?
| | Neoplasm Metastasis | 2 | 2014 | 658 | 0.100 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 79 | 0.100 |
Why?
| | Complementary Therapies | 1 | 2013 | 88 | 0.100 |
Why?
| | Maintenance Chemotherapy | 1 | 2012 | 35 | 0.100 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2012 | 17 | 0.090 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2012 | 63 | 0.090 |
Why?
| | Thyroid Neoplasms | 1 | 2015 | 343 | 0.090 |
Why?
| | Autocrine Communication | 1 | 2011 | 41 | 0.090 |
Why?
| | Carcinoma, Large Cell | 1 | 2011 | 16 | 0.090 |
Why?
| | Middle Aged | 12 | 2015 | 33479 | 0.090 |
Why?
| | Gene Rearrangement | 1 | 2011 | 150 | 0.080 |
Why?
| | Signal Transduction | 3 | 2013 | 5079 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 804 | 0.070 |
Why?
| | Radiotherapy | 1 | 2009 | 201 | 0.070 |
Why?
| | Biomedical Research | 1 | 2014 | 692 | 0.070 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 325 | 0.070 |
Why?
| | Genetic Testing | 1 | 2010 | 460 | 0.070 |
Why?
| | Humans | 19 | 2022 | 137585 | 0.070 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2007 | 43 | 0.070 |
Why?
| | Pleural Effusion | 1 | 2007 | 54 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2013 | 1276 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1236 | 0.060 |
Why?
| | Radiography | 1 | 2007 | 822 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 916 | 0.060 |
Why?
| | Everolimus | 2 | 2014 | 91 | 0.050 |
Why?
| | Celecoxib | 2 | 2013 | 39 | 0.050 |
Why?
| | Survival Rate | 3 | 2013 | 1972 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 2 | 2013 | 72 | 0.050 |
Why?
| | Male | 11 | 2015 | 67762 | 0.050 |
Why?
| | Incidence | 3 | 2015 | 2804 | 0.050 |
Why?
| | Oxazepines | 1 | 2022 | 5 | 0.050 |
Why?
| | Filgrastim | 1 | 2021 | 8 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2022 | 49 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 95 | 0.050 |
Why?
| | Infliximab | 1 | 2021 | 111 | 0.040 |
Why?
| | Female | 10 | 2015 | 73304 | 0.040 |
Why?
| | Aged | 7 | 2014 | 23961 | 0.040 |
Why?
| | United States | 4 | 2022 | 14841 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2013 | 7635 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 208 | 0.040 |
Why?
| | Imidazoles | 1 | 2022 | 238 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 366 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2011 | 317 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4030 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1710 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2012 | 10811 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 1809 | 0.030 |
Why?
| | Adult | 6 | 2014 | 37929 | 0.030 |
Why?
| | Michigan | 1 | 2015 | 109 | 0.030 |
Why?
| | Demography | 1 | 2015 | 291 | 0.030 |
Why?
| | Health Maintenance Organizations | 1 | 2014 | 108 | 0.030 |
Why?
| | Cetuximab | 1 | 2014 | 98 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2014 | 199 | 0.030 |
Why?
| | Ethmoid Sinus | 1 | 2013 | 10 | 0.030 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2013 | 8 | 0.030 |
Why?
| | Taxoids | 1 | 2013 | 102 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 686 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 219 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5131 | 0.020 |
Why?
| | Survival Analysis | 1 | 2015 | 1325 | 0.020 |
Why?
| | Submandibular Gland Neoplasms | 1 | 2012 | 1 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 786 | 0.020 |
Why?
| | Parotid Neoplasms | 1 | 2012 | 16 | 0.020 |
Why?
| | Salivary Gland Neoplasms | 1 | 2012 | 41 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2011 | 45 | 0.020 |
Why?
| | Pemetrexed | 1 | 2011 | 33 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 698 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1060 | 0.020 |
Why?
| | Glutamates | 1 | 2011 | 59 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 955 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 87 | 0.020 |
Why?
| | Guanine | 1 | 2011 | 79 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 889 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2011 | 164 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1226 | 0.020 |
Why?
| | ras Proteins | 1 | 2011 | 153 | 0.020 |
Why?
| | Cell Cycle | 1 | 2013 | 601 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 412 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 267 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3958 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 570 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1509 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2010 | 180 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 967 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1062 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 434 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1738 | 0.020 |
Why?
| | Registries | 1 | 2015 | 2035 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 648 | 0.020 |
Why?
| | Qualitative Research | 1 | 2013 | 1386 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2757 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2015 | 15657 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2475 | 0.010 |
Why?
| | Apoptosis | 1 | 2013 | 2553 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3412 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10388 | 0.010 |
Why?
| | Quality of Life | 1 | 2012 | 2892 | 0.010 |
Why?
| | Mice | 1 | 2013 | 17787 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 13209 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 21513 | 0.010 |
Why?
| | Child | 1 | 2012 | 21935 | 0.010 |
Why?
| | Animals | 1 | 2013 | 36940 | 0.010 |
Why?
|
|
Kono's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|